Phase 1 trial results show Covaxin has tolerable safety, enhanced immunity: Lancet study

India's first indigenous vaccine against COVID-19, Covaxin, showed enhanced immune response without any serious side effects in the participants enrolled for the phase 1 trials, according to the results published in The Lancet Infectious Disease journal. Developed by Bharat Biotech in collaboration with the ICMR and the National Institute of Virology (NIV), Pune, the vaccine has been granted emergency use authorisation in clinical trial mode' by the Indian government.